U.S. Stocks Movements: ImmunityBio surged on September 30 due to ANKTIVA expanded indications and FDA review
Bitget异动解读2026/09/30 14:20ImmunityBio September 30th Surge Analysis
Keywords: ANKTIVA expanded indications, FDA review
1. On September 30th, information was updated regarding ANKTIVA’s potential indication expansion, and the U.S. Food and Drug Administration intends to make a label expansion decision by January 6, 2027; the company’s September 11th patent application proposes combining ANKTIVA with checkpoint inhibitors, cancer vaccines, and engineered NK cells. Data from 98 non-small cell lung cancer cases shows a median survival of 21.1 months in patients with mild lymphocytopenia and 11.5 months in those with severe lymphocytopenia.
2. On September 30th, the GA-Courtenay Special Situations Fund highlighted ImmunityBio in its Q2 2026 investor letter; the company specializes in developing and commercializing next-generation immunotherapies, with its core Cancer BioShield platform based on the IL-15 superagonist ANKTIVA, covering natural killer cells, cytotoxic T cells, and memory T cells.
(Disclaimer: This content is generated by AI technology summarizing publicly available information for reference only, and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. gasoline inventories fell to their lowest level since November 2014 last week.
From Arizona to the "Silicon Prairie" in Texas: TSMC (TSM.US) may further expand its manufacturing footprint in the United States
Global semiconductor foundry leader TSMC (TSM.US) is assessing potential investments in Texas to expand its chip manufacturing operations in the United States.
Crypto prices
More
